Neuer Therapieansatz bei refraktärer CLL Arzerra® (Ofatumumab): Neuartiger CD20-Antikörper jetzt zugelassen

Publisher： Karger

E-ISSN： 2296-5262|33|7|403-406

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.33, Iss.7, 2010-06, pp. : 403-406

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B‐CLL: implications for rituximab resistance in CLL

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 2, 2015-04 ,pp. : 211-218

John Wiley & Sons Inc

Access to resources Recommend Favorite

Caelyx beim metastasierten Mammakarzinom zugelassen: Neue effektive Therapieoption mit besserer Verträglichkeit dank neuer Galenik

By  

Oncology Research and Treatment, Vol. 26, Iss. 2, 2003-05 ,pp. : 198-199

Karger

Access to resources Recommend Favorite

Ofatumumab‐based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL)

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3788-3796

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antikörper gegen impfpräventable Erkrankungen bei Schwangeren und deren Neugeborenen

By Sauerbrei A.  

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, Vol. 47, Iss. 1, 2004-01 ,pp. : 10-15

Springer Publishing Company

Access to resources Recommend Favorite

Antikörper gegen impfpräventable Erkrankungen bei Schwangeren und deren Neugeborenen

By Sauerbrei A.  

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, Vol. 47, Iss. 1, 2004-01 ,pp. : 16-20

Springer Publishing Company

Access to resources Recommend Favorite